Kuros Biosciences, a manufacturer of bone healing technologies, recently announced the publication of a peer-reviewed manuscript that details the clinical data of its MAXA Level 1 prospective, multi-center, randomized, intra-patient controlled clinical study in Spine1.
Published clinical results of “Efficacy of Biphasic Calcium Phosphate Ceramic with a Needle-shaped Surface Topography Versus Autograft in Instrumented Posterolateral Spinal Fusion: A Randomized Trial” include fusion data on 91 patients and 128 segments with 1-year follow-up after surgery. As previously reported and now detailed in the peer-reviewed publication, the data demonstrates:
- MagnetOsTM effectiveness as a standalone* alternative to autograft in challenging posterolateral fusions (PLF);
- Nearly double the fusion rate as compared to autograft in PLF, showin